QNRX.US Quoin Pharmaceuticals Ltd DRC

Healthcare Biotechnology USA Stocks
3.56 USD
Close of Nov 17, 2026
3.25 23.50
Market cap
USD 17.1M
P/E
8.1x
P/B
0.60x
ROE
-71.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is QNRX.US undervalued?

Graham number
Price3.56
Graham value7.66
Discount53.5%

QNRX.US trades 53.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Quoin Pharmaceuticals Ltd DRC fundamental analysis

No fundamental analysis for Quoin Pharmaceuticals Ltd DRC yet.

Quoin Pharmaceuticals Ltd DRC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Quoin Pharmaceuticals Ltd DRC

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, whic…

Full company profile